View Financial HealthWaters 配当と自社株買い配当金 基準チェック /06Waters配当金を支払った記録がありません。主要情報n/a配当利回り-0.009%バイバック利回り総株主利回り-0.009%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • May 06Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis.お知らせ • Apr 15Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large MoleculesWaters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026.お知らせ • Apr 10Waters Corporation, Annual General Meeting, May 21, 2026Waters Corporation, Annual General Meeting, May 21, 2026.お知らせ • Apr 08Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV AssayWaters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries.お知らせ • Mar 10Waters Corporation Launches ARES-G3 RheometerWaters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order.New Risk • Feb 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding).Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 10+ 1 more updateWaters Corporation Provides Earnings Guidance for the First Quarter Ending April 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the first quarter ending April 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue to be in the range of $1.198 billion to $1.211 billion on a reported basis and GAAP earnings per diluted share to be in the range of $0.05 to $0.15. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. and GAAP earnings per diluted share to be in the range of $6.63 to $6.83.お知らせ • Feb 09Waters Corporation Appoints Claire M. Fraser to Its Board of DirectorsWaters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.お知らせ • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026お知らせ • Nov 12Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower SoftwareWaters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026.お知らせ • Nov 05Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20. The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20.お知らせ • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025お知らせ • Aug 04+ 1 more updateWaters Corporation Raises Earnings Guidance for the Full Year 2025Waters Corporation raisedd earnings guidance for the full year 2025. For the quarter, the company expects constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.お知らせ • Jul 15Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing. The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026. Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts. Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.お知らせ • May 23Waters Corporation (NYSE:WAT) acquired Halo Labs.Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation. Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025.お知らせ • May 21Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc.Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025. Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025.決済の安定と成長配当データの取得安定した配当: 1WATの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 1WATの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Waters 配当利回り対市場1WAT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (1WAT)n/a市場下位25% (IT)1.7%市場トップ25% (IT)4.5%業界平均 (Life Sciences)0.8%アナリスト予想 (1WAT) (最長3年)0%注目すべき配当: 1WATは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 1WATは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 1WATの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 1WATが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIT 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 22:53終値2026/05/22 00:00収益2026/04/04年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Waters Corporation 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。39 アナリスト機関Catherine Ramsey SchulteBairdCharles ButlerBarclaysLuke SergottBarclays36 その他のアナリストを表示
Reported Earnings • May 08First quarter 2026 earnings released: US$0.88 loss per share (vs US$2.04 profit in 1Q 2025)First quarter 2026 results: US$0.88 loss per share (down from US$2.04 profit in 1Q 2025). Revenue: US$1.27b (up 92% from 1Q 2025). Net loss: US$72.0m (down 159% from profit in 1Q 2025). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 06Waters Corporation Provides Earnings Guidance for the Second Quarter Ending July 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the second quarter ending July 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue for the second quarter of 2026 is expected to be in the range of $1.616 billion to $1.631 billion. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis.
お知らせ • Apr 15Waters Corporation Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC Powering Rapid Characterization of Large MoleculesWaters Corporation announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio. Featuring 18 angles of detection, the omniDAWN Photometer is the first extended-range MALS detector for Ultra High Performance Liquid Chromatography (UHPLC) and Ultra Performance Liquid Chromatography (UPLC) workflows, delivering absolute molar mass and size measurements without compromising resolution or throughput. The omniDAWN MALS Photometer extends UPLC-compatible sizing ten-fold, from approximately 50 to 500 nm in radius, enabling reliable characterization of larger, more complex analytes such as protein aggregates, viral vectors, lipid nanoparticles (LNPs), and advanced materials. Because it provides absolute molar mass and size, the omniDAWN Photometer reduces reliance on column calibration standards and supports faster results and more confident comparisons, streamlining work across biosimilarity studies, antibody-drug conjugate (ADC) characterization, and viral vector analytics. Integrating seamlessly with Waters UPLC Systems and columns, the omniDAWN Photometer eliminates traditional trade-offs between dispersion, robustness, and analytical performance, delivering a complete solution for multi-attribute characterization with improved usability compared to micro-volume MALS approaches. When paired with UHPLC or UPLC Systems, the omniDAWN Photometer supports run times up to four times faster than conventional HPLC workflows, while reducing sample consumption by 30–50% and solvent use by approximately 40%. Its low dispersion design preserves resolution and sensitivity, while delivering high-quality data across complex samples. Sharper separations enhance the detection of low-level species, helping scientists distinguish monomer, aggregates, and fragments with greater clarity, supporting informed decision-making across discovery, development, and quality workflows. The omniDAWN Photometer is powered by ASTRA Software, built on more than 40 years of light scattering innovation. By integrating MALS with ultraviolet (UV) and refractive index (RI) detection, ASTRA Software enables comprehensive analysis of size, composition, and heterogeneity in a single run, with dedicated workflows for ADCs, LNPs, and viral vectors. The platform is 21 CFR Part 11 and EU Annex 11 compliant and will be compatible with Waters Empower Software later this year. The Waters omniDAWN MALS Photometer will be available globally in summer 2026.
お知らせ • Apr 10Waters Corporation, Annual General Meeting, May 21, 2026Waters Corporation, Annual General Meeting, May 21, 2026.
お知らせ • Apr 08Waters Corporation Announces U.S. Food and Drug Administration Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV AssayWaters Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening. Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the virus responsible for nearly all cervical cancers. Approximately 60% of cervical cancer cases occur in individuals who are unscreened or under-screened. Expanding screening options and access, including at-home self-collection, has been identified by public health experts as an instrumental strategy for improving early detection and reducing cervical cancer deaths. The kit is tested with the BD Onclarity HPV Assay, which detects all of the high-risk, carcinogenic genotypes of HPV and is the only FDA-approved HPV assay to identify six individually and three groups of pooled results, making it the most comprehensive HPV screening tool available in the U.S. today. Samples are processed on the fully automated BD COR System, which uses advanced robotics to prepare, analyze, and report results while preserving specimen integrity and ensuring reliable, high-quality outcomes. Waters collaborated with the National Institutes of Health's (NIH) National Cancer Institute (NCI) through the Cervical Cancer 'Last Mile' Initiative SHIP Trial to evaluate the accuracy of self-collection for HPV testing. Waters is currently establishing partnerships to enable broader nationwide access to the Onclarity HPV Self-Collection Kit, which is expected to be available by prescription in the coming months. Covered by private insurance, Medicaid, and Medicare, the kit can be mailed directly to a patient's home, allowing them to collect a sample at their convenience and mail it to a laboratory for processing. Results are shared with the patient's healthcare provider to guide follow-up and care decisions. The Onclarity HPV Self-Collection Kit, Onclarity HPV Assay, and BD COR System are manufactured by Becton, Dickinson and Company or one of its affiliates or subsidiaries.
お知らせ • Mar 10Waters Corporation Launches ARES-G3 RheometerWaters Corporation launched the ARES-G3 Rheometer, part of the TA Instruments product line. This next-generation rheometer delivers industry-leading speed paired with best-in-class data to accelerate materials research and product development. Capturing up to 25,000 data points per second (10x more than its predecessor) and cutting standard test times by up to 80% through fully integrated Fast Frequency Chirps, the ARES-G3 Rheometer addresses pressing industry limitations. The ARES-G3 Rheometer enables shortened experiment times, increased lab throughput, and previously unobtainable measurements of fast-changing samples in a single test. Because it fully integrates a Fast Frequency Chirps solution into its enhanced TRIOS Software, the ARES-G3 Rheometer eliminates the need for multiple software licenses and training in advanced programming packages to capture and process data through rapid frequency sweeps. Routine quality control tests and data generation can also be completed up to 80% faster than before with some tests reduced from six hours to one; this translates to accelerated workflows that save teams hundreds of workdays per year under typical conditions, without sacrificing data quality. The ARES-G3 Rheometer can also perform many tests without requiring user calibrations, reducing margin for human error and increasing confidence in measurements. The ARES-G3 Rheometer builds on the flagship legacy of its predecessor, improving at-instrument control with a new touchscreen, enhancing data capture with hardware and software updates, and preserving its core proprietary, fully integrated dynamic mechanical analysis (DMA) capabilities and purpose-built hardware for both stress measurement and strain control. Retaining the best-in-class oven of the ARES-G2 Rheometer, this next-generation rheometer delivers low-oxygen atmosphere control and temperature uniformity, further simplifying the process of simulating real-world processing conditions, and enabling scientists to explore new rheological methods and gain a deeper understanding of structure-property relationships. All existing ARES-G2 Rheometer methods and fixtures remain fully compatible with the ARES-G3 Rheometer. The Waters TA Instruments ARES-G3 Rheometer is available for order.
New Risk • Feb 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Shareholders have been substantially diluted in the past year (65% increase in shares outstanding).
Reported Earnings • Feb 13Full year 2025 earnings released: EPS: US$10.80 (vs US$10.75 in FY 2024)Full year 2025 results: EPS: US$10.80 (up from US$10.75 in FY 2024). Revenue: US$3.17b (up 7.0% from FY 2024). Net income: US$642.6m (flat on FY 2024). Profit margin: 20% (down from 22% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 10+ 1 more updateWaters Corporation Provides Earnings Guidance for the First Quarter Ending April 4, 2026 and Full Year Ending December 31, 2026Waters Corporation provided earnings guidance for the first quarter ending April 4, 2026 and full year ending December 31, 2026. For the quarter, the company expects total revenue to be in the range of $1.198 billion to $1.211 billion on a reported basis and GAAP earnings per diluted share to be in the range of $0.05 to $0.15. For the year, the company expects total revenue to be to be in the range of $6.405 billion to $6.455 billion on a reported basis. and GAAP earnings per diluted share to be in the range of $6.63 to $6.83.
お知らせ • Feb 09Waters Corporation Appoints Claire M. Fraser to Its Board of DirectorsWaters Corporation announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, effective upon the closing of the transaction. Dr. Fraser is a globally acclaimed genome scientist, with three decades of experience managing large research institutes. Most recently, she served as Director of The Institute for Genome Sciences, which she founded in 2007, at the University of Maryland School of Medicine, where she also served as a Professor of Medicine and Microbiology and Immunology. Dr. Fraser received a B.S. in Biology from Rensselaer Polytechnic Institute in Troy, NY, and a Ph.D. in Pharmacology from the State University of New York at Buffalo.
お知らせ • Jan 27Waters Corporation to Report Q4, 2025 Results on Feb 09, 2026Waters Corporation announced that they will report Q4, 2025 results on Feb 09, 2026
お知らせ • Nov 12Waters Corporation Boosts Lab Productivity and Sample Throughput with Launch of Its Charged Aerosol Detector Designed for Empower SoftwareWaters Corporation announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software. Waters is the global market leader in chromatography software solutions for regulatory filings, as Empower Software is used to submit data for approximately 80% of novel drugs to regulatory authorities. The Waters CAD delivers sensitive, consistent, and reproducible measurement of analytes with little or no UV absorption, including sugars, lipids, impurities, and excipients, often without the need for sample pre-treatment. This makes CAD ideal for characterizing an exceptionally broad range of materials, from small molecule and biopharmaceutical formulations to food additives, nutrients, and environmental pollutants. The Waters CAD delivers competitive dynamic range and sensitivity, alongside optimized compatibility with MaxPeak™? High-Performance Surfaces that mitigate non-specific adsorption. The new detector can be used with a wide range of Waters liquid chromatography systems, including the Alliancetm iS HPLC System, the Arctm HPLC System, and all ACQUITY™? UPLC™? Systems. The seamless integration of this CAD with broadly-adopted Empower Software delivers an enhanced user experience, supported by Waters' leading support and service provision. Issues commonly seen in multi-vendor LC-CAD systems, including challenging set-up and dropped communication between detector and chromatograph - leading to interrupted sample sets and in some cases detector flooding - are significantly reduced when using a Waters LC-CAD configured with Empower CDS. In addition, methods developed for existing CADs can be easily transferred using built-in tools. The introduction of the Waters Charged Aerosol Detect reinforces the Company's commitment to provide the world's widest range of liquid chromatography detectors, all compatible with Empower Software - enabling scientists to fully characterize the physical and chemical properties of molecules within a secure and compliant workflow. Availability: The Waters Charged Aerosoldetector (CAD) is available for pre-order now, with shipments available by April 2026.
お知らせ • Nov 05Waters Corporation Raises Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2025Waters Corporation raised earnings guidance for the fourth quarter and full year ending December 31, 2025. For the quarter, The company expects constant currency sales growth in the range of +5.0% to +7.0%. Net of currency translation, fourth quarter 2025 reported sales growth is expected in the range of +5.2% to +7.2%. The company expects GAAP earnings per diluted share in the range of $4.10 - $4.20. The Company is raising its full-year 2025 constant currency sales growth guidance to the range of +6.7% to +7.3%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%. The company expects GAAP earnings per diluted share in the range of $11.10 - $11.20.
お知らせ • Oct 01Waters Corporation to Report Q3, 2025 Results on Nov 04, 2025Waters Corporation announced that they will report Q3, 2025 results on Nov 04, 2025
お知らせ • Aug 04+ 1 more updateWaters Corporation Raises Earnings Guidance for the Full Year 2025Waters Corporation raisedd earnings guidance for the full year 2025. For the quarter, the company expects constant currency sales growth guidance to the range of +5.5% to +7.5%. Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +5.0% to +7.0%.
お知らせ • Jul 15Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion.Waters Corporation (NYSE:WAT) entered into a definitive agreement to acquire Biosciences and Diagnostics Solutions Business of Becton Dickinson and Company in a transaction valued at $17.5 billion on July 13, 2025. BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters shareholders are expected to own approximately 60.8% of the combined company. BD will also receive a cash distribution of approximately $4 billion prior to completion of the combination, subject to adjustment for cash, working capital, and indebtedness. Waters is expected to assume approximately $4 billion of incremental debt, which would result in a net-debt-to-adjusted EBITDA leverage ratio for the combined company of 2.3x at closing. The transaction is subject to receipt of required regulatory approvals, Waters shareholder approval, Any applicable waiting period under the HSR Act and satisfaction of other customary closing conditions. It was subject to approval by Boards of Directors of Waters and BD and has been unanimously approved by the Boards of Directors of both Waters and BD. The transaction is expected to close around the end of the first quarter of calendar year 2026. Upon closing of the transaction, Udit Batra will lead the new entity, and Amol Chaubal will serve as SVP and Chief Financial Officer. Executives from both companies will serve in key leadership roles to be announced at a later date. Up to two BD designees will join the Waters Board of Directors upon closing. The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters’ headquarters will remain in Milford, Massachusetts. Barclays is serving as financial advisor and Daniel E. Wolf, P.C., David M. Klein, P.C., Allie M. Wein, P.C. and Steven M. Choi of Kirkland & Ellis LLP is serving as legal advisor to Waters. Citi and Evercore is acting as lead financial advisor to BD. David K. Lam and Jenna E. Levine of Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.
お知らせ • May 23Waters Corporation (NYSE:WAT) acquired Halo Labs.Waters Corporation (NYSE:WAT) acquired Halo Labs on May 21, 2025. Halo Labs, Aura, and Wyatt Technology are trademarks of Waters Technologies Corporation. Waters Corporation (NYSE:WAT) completed the acquisition of Halo Labs on May 21, 2025.
お知らせ • May 21Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc.Waters Corporation (NYSE:WAT) acquired Optofluidics, Inc. on May 21, 2025. Waters Corporation (NYSE:WAT) completed the acquisition of Optofluidics, Inc. on May 21, 2025.